Home » Stocks » ERAS

Erasca, Inc. (ERAS)

Stock Price: $18.96 USD 0.11 (0.58%)
Updated Jul 27, 2021 4:00 PM EDT - Market closed
Market Cap 2.20B
Revenue (ttm) n/a
Net Income (ttm) -96.02M
Shares Out 116.14M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 27
Last Price $18.96
Previous Close $18.85
Change ($) 0.11
Change (%) 0.58%
Day's Open 19.00
Day's Range 18.20 - 19.31
Day's Volume 152,533
52-Week Range 14.51 - 20.27

News

Hide News

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...

1 week ago - GlobeNewsWire

SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...

1 week ago - GlobeNewsWire

Erasca, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About ERAS

Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS and the MAPK pathway account for approximately 5.5 million new cases of cancer worldwide per year. We have assembled what we believe to be the deepest, wholly-owned or controlled RAS/MAPK pathway-focused pipeline in the industry, comprising 11 modality-agnostic programs aligned with our three therapeutic strategies of: (1) targeting key ... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Jul 16, 2021
CEO
Jonathan E. Lim, M.D.
Employees
102
Stock Exchange
NASDAQ
Ticker Symbol
ERAS
Full Company Profile

Financial Performance

Financial Statements